Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -1.61.EBIT: As of FY2026 Q1, the actual value is USD -5.33 M.<h4>Segment Revenue</h4>To date, Tevogen Bio Holdings Inc. has not generated any revenue .<h4>Operational Metrics</h4><ul><li>Net Loss: Net loss for the three months ended March 31, 2026, was - $5,446,255, a decrease compared to - $10,367,061 for the three months ended March 31, 2025 .</li><li>Total Operating Expenses: Total operating expenses were $5,400,920 for the three months ended March 31, 2026, down from $10,356,347 for the same period in 2025 .</li><li>Research and Development (R&amp;D) Expenses: R&amp;D expenses were $3,134,810 for the three months ended March 31, 2026, a slight decrease from $3,195,068 for the three months ended March 31, 2025, primarily due to lower personnel costs .</li><li>General and Administrative (G&amp;A) Expenses: G&amp;A expenses decreased to $2,266,110 for the three months ended March 31, 2026, from $7,161,279 for the three months ended March 31, 2025, mainly due to lower legal and professional fees and non-cash stock-based compensation expense .</li><li>Interest Expense, Net: Interest expense, net, increased to - $71,166 for the three months ended March 31, 2026, from - $24,571 for the same period in 2025 .</li><li>Change in Fair Value of Warrants: A gain of $25,831 was recognized for the three months ended March 31, 2026, compared to a gain of $13,857 for the three months ended March 31, 2025 .</li><li>Stock-Based Compensation Expense: Total stock-based compensation expense was $2,849,592 for the three months ended March 31, 2026, a decrease from $7,292,701 for the three months ended March 31, 2025 .</li></ul><h4>Cash Flow</h4><ul><li>Cash Flow from Operating Activities: Net cash used in operating activities was - $2,733,769 for the three months ended March 31, 2026, compared to - $3,308,063 for the three months ended March 31, 2025 .</li><li>Cash Flow from Investing Activities: There were no cash flows from investing activities for both periods .</li><li>Cash Flow from Financing Activities: Net cash provided by financing activities was $2,873,702 for the three months ended March 31, 2026, including $2,000,000 from the Loan Agreement and $873,702 from the Sales Agreement . For the same period in 2025, financing activities provided $4,000,000, consisting of a $2,000,000 draw on the Loan Agreement and a $2,000,000 KRHP grant .</li></ul><h4>Liquidity and Funding</h4>As of March 31, 2026, Tevogen Bio Holdings Inc. had cash of $0.7 million . Subsequent to March 31, 2026, the company received $0.1 million from sales under the Sales Agreement and $3.0 million from the sale of prefunded common stock purchase warrants in May 2026 . Additionally, $14.0 million remains available under the Loan Agreement, and there is a remaining commitment for a $7.0 million grant from KRHP .<h4>Future Outlook and Strategy</h4>Tevogen Bio Holdings Inc. anticipates incurring additional losses until significant sales are generated from product candidates and expects R&amp;D and G&amp;A expenses to increase as it expands manufacturing, conducts clinical trials, and prepares regulatory filings . The company believes current cash combined with expected proceeds will provide adequate financial resources for at least the next 12 months, though clinical trials will not initiate until additional funding is received . The company regularly evaluates funding strategies including private placements, licensing, partnerships, and public offerings of securities .

TEVOGEN BIO HOLDINGS INC C/WTS 14/02/2029 (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0